Precision Assessment of Anti-NMDA Receptor Encephalitis: A Case Report on Integrating Clinical Course, Immunophenotyping, and Comprehensive Symptomatology in a Pediatric Patient With Adjunctive Hydrogen Therapy.
Lin SC, Lu JW, Lin TC, Sung YF, Ho YJ, Wang FM, Lui SW, Hsieh TY, Wang KY, Liu FC. · In Vivo. 2025;39:13858.
Study at a glance
Human
One pediatric patient with anti-NMDA receptor encephalitis receiving intensive immunotherapy.
One oral hydrogen-generating capsule daily as adjunctive therapy. · Systemic hydrogen exposure was not directly measured.
Follow-up over the treatment timeline reported in the article.
The report describes clinical and immunologic changes after hydrogen was added to rituximab, intravenous immunoglobulin and other care.
Concurrent intensive treatment and natural recovery make causal attribution to hydrogen impossible.
What kind of evidence is this?
Human
Case report
Other neurological conditions
Other forms
Indeterminate for molecular hydrogen.
Clinical and biomarker outcomes in a single patient.
Methods
One pediatric patient with anti-NMDA receptor encephalitis receiving intensive immunotherapy.
1 patient.
Follow-up over the treatment timeline reported in the article.
One oral hydrogen-generating capsule daily as adjunctive therapy.
Hydrogen generated after capsule ingestion; not Brown's gas.
Systemic hydrogen exposure was not directly measured.
No control; longitudinal clinical course.
Outcomes and reported result
Neurologic symptoms, clinical course and immune phenotyping.
The report describes clinical and immunologic changes after hydrogen was added to rituximab, intravenous immunoglobulin and other care.
The full case report, treatment timeline, clinical observations and immune measurements were checked.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Concurrent intensive treatment and natural recovery make causal attribution to hydrogen impossible.
This individual case only.
JBI Case Report Checklist — preliminary
Serious concerns
No comparator and major time-varying confounding from immunotherapy and supportive care.
Single selected case · Co-interventions were present · Follow-up described in the report · Several outcomes were clinician- or patient-reported · No prespecified analysis plan
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 39740868 · DOI: 10.21873/invivo.13858
Free full article in PubMed Central.
PubMed record and PubMed Central full text; extraction checked 9 August 2026.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.